MINSK, 15 May (BelTA) - SZAO Industrial Park Development Company and the Center for Examinations and Tests in Healthcare have signed a memorandum of cooperation in a ceremony in the Great Stone Industrial Park, BelTA learned from the press service of the Healthcare Ministry.
Demand for high-quality medical services and medicines has increased greatly amid the pandemic, and today the Great Stone has created all opportunities for companies to work in this area, Aleksandr Yaroshenko, Head of the Administration of the China-Belarus Industrial Park Great Stone, said at the official signing event.
"The pandemic has shown that nothing is more important than health. The park has created all the conditions for the manufacture of pharmaceutical products. Twelve of our resident companies specialize in this business. These are companies from Belarus, China, Czech Republic, Estonia, Russia, and the USA. Soon we are branching into a new line of business - traditional Chinese medicine," said Aleksandr Yaroshenko.
He stressed that this is about opening of a center to provide appropriate services, launching of production of drugs, medicines and other medical products in Belarus. According to him, the Great Stone industrial park is mulling over launching the production of a COVID-19 vaccine on its premises.
The signing of the memorandum is another step towards strengthening the friendly relations between Belarus and China, Belarusian Deputy Healthcare Minister Boris Androsyuk noted. “When the pandemic broke out, Belarus was the first to lend China a helping hand. China returned the favor when the pandemic reached Belarus. We cooperate and help each other at all levels,” he said.
According to Director of the Center for Examinations and Tests in Healthcare Dmitry Grinko, in line with the memorandum, the parties will establish a partnership and develop long-term, effective, mutually beneficial cooperation, including at the international level in order to implement the policy of the Healthcare Ministry aimed at ensuring safety, effectiveness, and high quality of medicines, pharmaceutical substances, and medical products. The document also provides for participation in joint R&D consultations, symposiums, seminars, forums, and conferences.
“Amid the COVID-19 pandemic, it is especially important to spread awareness of regulations in the field of sales of medical products, medicines, and pharmaceutical substance in the Eurasian Economic Union among investors, residents companies, and partners of the industrial park,” Dmitry Grinko added.
